Tambocor Dispute, FTC Report May Keep Generic Drugs On Congress' Agenda
Executive Summary
A dispute between Par and Barr over generic exclusivity for flecainide reflects the continued complexities in the Waxman/Hatch process that could drive Congressional action over the next 18 months.
You may also be interested in...
Par Responds To Process Patents: FineTech Acquisition Valued At $109 Mil.
Par's acquisition of ISP's FineTech chemical business reflects the generic drug company's desire to gain greater control over all aspects of the manufacturing process in the current environment of patent disputes
Taxol Ruling Re-Emphasizes “Ministerial” Role For FDA On Patents
The Taxol appeals court ruling may make it more difficult for FDA to stray from a "ministerial" approach to "Orange Book" patent listings
Barr Generic Ortho-Novum 7/7/7 To Launch Nine Months Prior To Patent Expiry
Barr will launch Nortrel 7/7/7, its generic of Ortho-McNeil's Ortho-Novum 7/7/7, in January 2003 per an Oct. 29 patent litigation settlement